IFNA2 and ovarian cancer: In vivo studies in ovarian cancer xenograft mouse models showed that HA-IFNα-2a bioconjugate exhibited a superior antitumor activity without being toxic for intraperitoneal organs in comparison with the free IFNα-2a.